-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
SpringWorks Therapeutics (NASDAQ:SWTX) Stock Price Down 4.7%
SpringWorks Therapeutics (NASDAQ:SWTX) Stock Price Down 4.7%
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Get Rating) traded down 4.7% on Tuesday . The stock traded as low as $26.14 and last traded at $26.24. 1,235 shares changed hands during mid-day trading, a decline of 100% from the average session volume of 966,095 shares. The stock had previously closed at $27.52.
Wall Street Analyst Weigh In
Several equities research analysts have recently weighed in on the company. Wedbush set a $53.00 target price on SpringWorks Therapeutics in a research report on Monday, June 20th. HC Wainwright upped their price objective on SpringWorks Therapeutics from $94.00 to $103.00 and gave the company a "buy" rating in a research note on Monday, September 12th. Finally, The Goldman Sachs Group dropped their price target on SpringWorks Therapeutics from $92.00 to $76.00 and set a "buy" rating on the stock in a research report on Tuesday, May 24th.
Get SpringWorks Therapeutics alerts:SpringWorks Therapeutics Price Performance
The company has a 50-day moving average price of $29.17 and a 200-day moving average price of $36.72.
SpringWorks Therapeutics (NASDAQ:SWTX – Get Rating) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.26) by ($0.15). During the same quarter in the prior year, the business earned ($0.97) earnings per share. The firm's quarterly revenue was up .0% on a year-over-year basis. Sell-side analysts predict that SpringWorks Therapeutics, Inc. will post -5.36 EPS for the current year.Insider Buying and Selling
In related news, major shareholder Orbimed Advisors Llc sold 153,897 shares of SpringWorks Therapeutics stock in a transaction dated Monday, September 12th. The stock was sold at an average price of $31.96, for a total transaction of $4,918,548.12. Following the sale, the insider now directly owns 5,599,842 shares of the company's stock, valued at $178,970,950.32. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 28.95% of the stock is owned by company insiders.
Hedge Funds Weigh In On SpringWorks Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in the company. State Street Corp raised its holdings in SpringWorks Therapeutics by 143.7% in the 2nd quarter. State Street Corp now owns 3,889,249 shares of the company's stock valued at $95,753,000 after acquiring an additional 2,293,359 shares during the period. FMR LLC grew its holdings in shares of SpringWorks Therapeutics by 22.6% during the second quarter. FMR LLC now owns 7,412,040 shares of the company's stock valued at $182,484,000 after buying an additional 1,365,831 shares during the last quarter. Nomura Holdings Inc. purchased a new position in SpringWorks Therapeutics during the second quarter worth about $13,432,000. Pictet Asset Management SA raised its position in shares of SpringWorks Therapeutics by 74.2% in the second quarter. Pictet Asset Management SA now owns 1,103,577 shares of the company's stock valued at $27,170,000 after purchasing an additional 470,129 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in SpringWorks Therapeutics by 522.3% during the second quarter. JPMorgan Chase & Co. now owns 526,829 shares of the company's stock valued at $12,971,000 after acquiring an additional 442,164 shares in the last quarter.
SpringWorks Therapeutics Company Profile
(Get Rating)
SpringWorks Therapeutics, Inc acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors.
Featured Stories
- Get a free copy of the StockNews.com research report on SpringWorks Therapeutics (SWTX)
- Has AMD stock stock fallen too far?
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Get Rating) traded down 4.7% on Tuesday . The stock traded as low as $26.14 and last traded at $26.24. 1,235 shares changed hands during mid-day trading, a decline of 100% from the average session volume of 966,095 shares. The stock had previously closed at $27.52.
SpringWorks治疗公司(纳斯达克代码:SWTX-GET评级)周二下跌4.7%。该股一度跌至26.14美元,最后报26.24美元。午盘交易中,1,235股易手,较966,095股的平均成交量下降了100%。该股此前收盘价为27.52美元。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
Several equities research analysts have recently weighed in on the company. Wedbush set a $53.00 target price on SpringWorks Therapeutics in a research report on Monday, June 20th. HC Wainwright upped their price objective on SpringWorks Therapeutics from $94.00 to $103.00 and gave the company a "buy" rating in a research note on Monday, September 12th. Finally, The Goldman Sachs Group dropped their price target on SpringWorks Therapeutics from $92.00 to $76.00 and set a "buy" rating on the stock in a research report on Tuesday, May 24th.
几位股票研究分析师最近对该公司进行了分析。韦德布什在6月20日星期一的一份研究报告中为SpringWorks治疗公司设定了53.00美元的目标价格。9月12日,周一,HC Wainwright将SpringWorks治疗公司的目标价从94美元上调至103.00美元,并在一份研究报告中给予该公司“买入”评级。最后,高盛夫妇在5月24日(星期二)的一份研究报告中将SpringWorks Treateutics的目标价从92.00美元下调至76.00美元,并对该股设定了“买入”评级。
SpringWorks Therapeutics Price Performance
SpringWorks治疗公司的性价比
The company has a 50-day moving average price of $29.17 and a 200-day moving average price of $36.72.
该公司的50日移动均线价格为29.17美元,200日移动均线价格为36.72美元。
Insider Buying and Selling
内幕买卖
In related news, major shareholder Orbimed Advisors Llc sold 153,897 shares of SpringWorks Therapeutics stock in a transaction dated Monday, September 12th. The stock was sold at an average price of $31.96, for a total transaction of $4,918,548.12. Following the sale, the insider now directly owns 5,599,842 shares of the company's stock, valued at $178,970,950.32. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 28.95% of the stock is owned by company insiders.
相关新闻,大股东Orbimed Advisors LLC在9月12日(星期一)的交易中出售了153,897股SpringWorks治疗公司的股票。该股以31.96美元的平均价格出售,总成交金额为4918,548.12美元。出售后,这位内部人士现在直接持有该公司5,599,842股股票,价值178,970,950.32美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,可以通过以下链接访问该文件。28.95%的股份由公司内部人士持有。
Hedge Funds Weigh In On SpringWorks Therapeutics
对冲基金入股SpringWorks Treateutics
Several institutional investors and hedge funds have recently made changes to their positions in the company. State Street Corp raised its holdings in SpringWorks Therapeutics by 143.7% in the 2nd quarter. State Street Corp now owns 3,889,249 shares of the company's stock valued at $95,753,000 after acquiring an additional 2,293,359 shares during the period. FMR LLC grew its holdings in shares of SpringWorks Therapeutics by 22.6% during the second quarter. FMR LLC now owns 7,412,040 shares of the company's stock valued at $182,484,000 after buying an additional 1,365,831 shares during the last quarter. Nomura Holdings Inc. purchased a new position in SpringWorks Therapeutics during the second quarter worth about $13,432,000. Pictet Asset Management SA raised its position in shares of SpringWorks Therapeutics by 74.2% in the second quarter. Pictet Asset Management SA now owns 1,103,577 shares of the company's stock valued at $27,170,000 after purchasing an additional 470,129 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in SpringWorks Therapeutics by 522.3% during the second quarter. JPMorgan Chase & Co. now owns 526,829 shares of the company's stock valued at $12,971,000 after acquiring an additional 442,164 shares in the last quarter.
几家机构投资者和对冲基金最近对他们在该公司的头寸进行了调整。道富集团在第二季度增持了SpringWorks Treateutics 143.7%的股份。道富银行目前持有该公司3,889,249股股票,价值95,753,000美元,在此期间又收购了2,293,359股。FMR LLC在第二季度增持了SpringWorks Treateutics的股票22.6%。FMR LLC现在拥有该公司7,412,040股股票,价值182,484,000美元,上个季度又购买了1,365,831股。野村控股(Nomura Holdings Inc.)在第二季度购买了SpringWorks Treateutics的新头寸,价值约13,43.2万美元。Pictet Asset Management SA在第二季度将其在SpringWorks Treateutics的股票头寸提高了74.2%。Pictet Asset Management SA现在拥有1,103,577股该公司的股票,价值27,170,000美元,在此期间又购买了470,129股。最后,摩根大通在第二季度增持了SpringWorks Treateutics的股份522.3%。摩根大通目前持有该公司526,829股股票,价值12,971,000美元,上一季度又购入了442,164股。
SpringWorks Therapeutics Company Profile
SpringWorks治疗公司简介
(Get Rating)
(获取评级)
SpringWorks Therapeutics, Inc acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors.
SpringWorks治疗公司为患有罕见疾病和癌症的未得到充分服务的患者群体收购、开发和商业化药物。它的主要候选产品是Niroacestat,一种口服小分子伽马分泌酶抑制剂,正在进行治疗韧带样肿瘤的第三阶段临床试验。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on SpringWorks Therapeutics (SWTX)
- Has AMD stock stock fallen too far?
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- 免费获取StockNews.com关于SpringWorks治疗公司(SWTX)的研究报告
- AMD股票是不是跌得太厉害了?
- 甲骨文的短期痛苦可能是你的长期收益
- Lucid看起来像是电动汽车的赢家
- 仍然爱着它:投资者继续光顾麦当劳
- 联邦快递刚刚提供了一个买入机会吗?
Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
获得SpringWorks治疗日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对SpringWorks Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧